Gilead acquires drug candidate for $1.275bn
Gilead will acquire PepStar Therapeutics' oral IL-23R inhibitor program, including HCXT-2001, for $1.275bn. The deal, expected to close in Q4 2026, will reduce Gilead's EPS by $0.79 to $0.83 in that quarter. Gilead plans to evaluate HCXT-2001 for IBD and psoriasis, alone or with emvistegrast.
How this was made
The 30-second read
Why it matters
The $1.275 bn cash deal will dilute earnings in Q4 2026 but may provide a differentiated product in IBD and psoriasis.
Market read
Primary M&A news for Gilead; immediate EPS impact and cash outflow drive short‑term price risk.
What to watch
Potential synergies with Gilead's existing pipeline and long‑term revenue growth beyond the EPS hit.
Background
Gilead (GILD) is a large US‑listed biopharma expanding its oral pipeline with an IL‑23R inhibitor.
Ticker impact
Gilead announced a $1.275 bn acquisition of PepStar's IL‑23R program, impacting Q4 2026 EPS.
likely downward pressure as market prices in EPS reduction
The deal reduces GAAP and non‑GAAP EPS by $0.79‑$0.83 and involves a sizable cash outlay.
Market effects
Adds to consolidation in the IBD/psoriasis therapeutic space, may spur competitor M&A activity.
US biotech sector sees modest negative bias due to cash deployment.
Limited to pharma investors; no broad market effect.
Counterpoint
The acquisition could unlock a high‑margin oral therapy, offering upside if development succeeds.
Key entities
- CompanyGilead Sciences
US‑listed biopharma acquiring the IL‑23R program.
- CompanyPepStar Therapeutics
Privately held developer of the HCXT‑2001 program.
